|1.||Saltarelli, Mario D: 4 articles (07/2015 - 01/2011)|
|2.||Abi-Saab, Walid M: 3 articles (07/2015 - 01/2011)|
|3.||Decker, Michael W: 3 articles (04/2014 - 01/2004)|
|4.||Robieson, Weining Z: 3 articles (06/2012 - 01/2011)|
|5.||Apostol, George: 3 articles (06/2012 - 01/2011)|
|6.||Wilens, Timothy E: 3 articles (01/2011 - 06/2006)|
|7.||Pritchett, Yili L: 2 articles (07/2015 - 02/2012)|
|8.||Zhang, Danhui: 2 articles (10/2014 - 04/2014)|
|9.||Bordia, Tanuja: 2 articles (10/2014 - 04/2014)|
|10.||Quik, Maryka: 2 articles (10/2014 - 04/2014)|
|1.||Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
01/01/2011 - "Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials."
01/01/2011 - "To assess the safety and efficacy of ABT-089, a novel α(4)β(2) neuronal nicotinic receptor partial agonist, vs. placebo in children with attention-deficit/hyperactivity disorder (ADHD). "
06/01/2012 - "ABT-089, an α4β2 neuronal nicotinic receptor partial agonist (generic name pozanicline), has demonstrated efficacy in adults with attention-deficit/hyperactivity disorder (ADHD) at doses of 40 mg once daily and 40 mg twice daily. "
06/01/2012 - "A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder."
02/01/2012 - "Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study."
|2.||Alzheimer Disease (Alzheimer's Disease)
07/01/2015 - "Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease."
07/01/2015 - "When administered as adjunctive therapy to acetylcholinesterase inhibitors, ABT-089 was not efficacious in mild to moderate Alzheimer disease. "
07/01/2015 - "ABT-089, an α4β2 neuronal nicotinic receptor partial agonist, was evaluated for efficacy and safety in mild to moderate Alzheimer disease patients receiving stable doses of acetylcholinesterase inhibitors. "
04/01/2014 - "ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease."
10/01/2014 - "The general nAChR agonist nicotine, as well as several nAChR agonists (varenicline, ABT-089 and ABT-894), reduces l-dopa-induced abnormal involuntary movements or dyskinesias up to 60% in parkinsonian nonhuman primates and rodents. "
|1.||Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
|2.||Levodopa (L Dopa)
|3.||Measles-Mumps-Rubella Vaccine (MMR Vaccine)
|4.||Succinic Acid (Succinate)
|7.||Etidronic Acid (HEDP)